Singular Genomics Systems, Inc. Stock Price, News & Analysis

Singular Genomics Systems (Nasdaq: OMIC) is set to showcase the G4 Sequencing Platform at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 1:30 p.m. PT.

The event will be held virtually, allowing investors to access the presentation via a live and recorded webcast on the company's investor relations website. Singular Genomics focuses on advancing genomics through innovative next-generation sequencing (NGS) and multiomics technologies, with a mission to enhance scientific and medical advancements.

Singular Genomics Systems, Inc. (Nasdaq: OMIC) has announced the appointment of Elaine R. Mardis, Ph.D., to its Board of Directors. Dr. Mardis is a renowned expert in cancer genomics, recognized for her contributions to genomic technologies aimed at enhancing disease understanding and precision medicine.

The CEO, Drew Spaventa, expressed enthusiasm for her unique expertise, which aligns with the company's focus on advancing clinical sequencing solutions. Dr. Mardis's extensive background includes leadership roles in genomic medicine and significant publications in medical research.

Singular Genomics Systems (Nasdaq: OMIC) has announced a collaboration with the Broad Institute to integrate its G4 sequencer with Terra, a cloud-based data platform. This partnership aims to enhance biomedical research by providing seamless access to analytical tools and cloud storage optimized for genomic data. The integration is designed to facilitate data analysis and sharing, empowering researchers to advance their work more efficiently. Both parties anticipate this collaboration will pave the way for future offerings that complement the capabilities of the G4 sequencer.

Singular Genomics Systems, Inc. (NASDAQ: OMIC) has launched the G4 Sequencing Platform, boasting up to three times more data output per hour than existing benchtop sequencers. This innovative next-generation sequencing (NGS) platform integrates advanced chemistry and engineering to enhance accuracy, speed, and flexibility for various applications, particularly in oncology and immunology. Orders are currently being accepted, with shipments anticipated to commence in Q2 2022. The G4 can run up to 16 samples simultaneously, significantly reducing run times and operational costs.

Singular Genomics Systems, Inc. (Nasdaq: OMIC) reported its third-quarter 2021 financial results, highlighting successful early access partnerships for the G4 Integrated Solution. The company achieved targeted performance metrics in labs with accuracy rates between 99.6% to 99.8% and significant average read counts. Operating expenses rose to $17.5 million, driven by headcount growth and G4 launch investments, resulting in a net loss of $17.6 million. Cash reserves stood at approximately $357 million, with the commercial launch for G4 expected by year-end 2021 and shipments slated for the first half of 2022.

Singular Genomics Systems will report its Q3 2021 financial results after market close on November 9, 2021. Management will host a conference call at 1:30 PM PT to discuss these results. Singular Genomics focuses on advancing genomic technologies, offering products like the Singular Sequencing Engine and developing integrated solutions such as the G4 Integrated Solution for NGS and the PX Integrated Solution for multiomics applications.

Singular Genomics Systems will participate in a fireside chat at the UBS Genomics 2.0 and MedTech Innovations Summit on August 11, 2021, at 3:00 PM PT. CEO Drew Spaventa and CSO Eli Glezer will discuss the company's advancements in genomic technologies. Investors can listen live through the company's website, with an archived version available after the event. Singular Genomics focuses on novel next-generation sequencing and multiomics technologies, aiming to accelerate genomics for scientific and medical progress.